Bioxcel therapeutics announces clinical prioritization and update on bxcl501 late-stage programs for agitation

Recently initiated serenity at-home pivotal phase 3 trial for agitation associated with bipolar disorders or schizophrenia

BTAI Ratings Summary

BTAI Quant Ranking